>Accreditation - CME
Officially Endorsed by:
UCSD Sulpizio Cardiovascular Center
The Heart Failure Society of America
American College of Cardiology
November 30 - December 2, 2017
International Hawaii Symposium on
Diagnostic and Therapeutic Modalities in Heart Failure
A Comprehensive and Practical Review of Advances in
Heart Failure and Biomarkers
Mauna Lani Bay Hotel and Bungalows
Kohala Coast, Island of Hawaii
IMPORTANT CME CREDIT INFORMATION
Required CME Surveys will be available online once the conference begins. Your email address and registration confirmation code are needed in order for you to login and
complete the surveys. Upon completion you will receive your CME Certificate online. Surveys must be completed by December 24, 2017.
2017 CME SURVEYS/CERTIFICATE and CONFERENCE MATERIALS
This Live activity, 7th Annual International Hawaii Symposium on Diagnostic
and Therapeutic Modalities in Heart Failure, with a beginning date of
November 30, 2017 has been reviewed and is acceptable for up to 14.75
Prescribed credit(s) by the American Academy of Family Physicians. Physicians
should claim only the credit commensurate with the extent of their participation
in the activity.
AMA: AAFP Prescribed credit is accepted by the American Medical Association
as equivalent to AMA PRA Category 1 Credit™ toward the
AMA Physician's Recognition Award.
AANPCP: The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AAFP Prescribed credit.
ANCC: According to the ANCC, the continuing education hours approved by
the AAFP meet the ANCC-accredited CNE criteria.
AAPA: The American Academy of Physician Assistants accepts AAFP Prescribed
credit for AAPA Category 1 CME credit.
The 7th Annual International Hawaii Symposium on Diagnostic and
Therapeutic Modalities in Heart Failure will
be held from Nov 30 - Dec 2 at the delightful
Mauna Lani Hotel on the beautiful Island of
Hawaii. This year we have put together a program
that is designed to provide in depth coverage
of the important advances that have
taken place in heart failure over the past year as well as provide an overview
of the most effective therapeutic strategies for prevention and treatment.
Topics will be covered through a series of lectures, panel discussions
and case presentations.
At the end of the meeting the participant will be better able to:
1. Implement effective therapy for treating heart failure patients with pharmacologic agents and devices
2. Recognize the role of new FDA approved heart failure drugs
3. Describe new anticoagulants to treat atrial fibrillation and other cardiovascular diseases
4. Define patients who are candidates for the use of left atrial appendage closure devices
5. Determine how remote monitoring devices and biomarkers help in patient management
6. Evaluate and manage patients with pulmonary arterial hypertension
7. Define indications for percutaneous mitral repair and aortic valve replacement
8. Identify patients who are candidates for ICDs and CRT
9. Describe the value of a wearable cardioverter defibrillator
10. Explore novel “biomarkers” such as pulmonary pressure, serum potassium,
apnea/hypopnea index, and how this will lead to new and effective targeted
11. Describe new agents to treat hypercholesterolemia and diabetes
Nearly 6 million Americans (two percent of the U.S.) are living with heart failure. An estimated 670,000 new cases of heart failure (HF) are diagnosed each year and this condition is a major cause of morbidity and mortality (80% of men and 70% of women less than 65 years of age who have HF will die within 8 years) and is the number one cause of hospitalizations of the elderly in the US. HF is common, but unrecognized and often misdiagnosed. Recent data have shown that drugs and devices that have proven beneficial and are recommended in recent practice guidelines, (HFSA 2010 update of practice guidelines Lindelfield J et al J Cardiac Failure 2010;16: 475) are underutilized (Fonarow GC et al. Circulation 2010;122:585).
Recent information also suggests a significant individual variability in conformity to quality-of-care indicators and clinical outcome of patients with HF and a substantial gap in overall performance. In addition, according to a study analyzing the quality of health care in the US on average, patients with heart failure received the recommended quality of care only 64% of the time (heart failure performance measurement set by the ACC/AHA 2010). Using data from the IMPROVE-HF registry it was found that only 7% of HF patients received all therapies for which they were potentially eligible and use of guideline recommended therapy by practices varied widely (Fonarow GC et al Circ Heart Failure 2008;1:98).
The importance of correcting deficiencies in knowledge and practice is evidenced from the results of recent studies demonstrating that increased use of evidence based, life sustaining therapies and performance measures have a significant impact on the outcome of patients with HF (OPTIMIZE- HF, JAMA 2007; 297: 61).
The target audience for this activity includes Cardiologists, Internists, Primary Care Physicians, Nurses, Nurse Practitioners, Physician Assistants, PharmDs and Allied Health Care Professionals.